2003
DOI: 10.1046/j.1365-2141.2003.04161.x
|View full text |Cite
|
Sign up to set email alerts
|

Factor VII/VIIa: a new antigen in the anti‐phospholipid antibody syndrome

Abstract: We investigated antibodies to factor VII/VIIa (FVII/VIIa) and five other common target antigens in 33 patients with a history of anti-phospholipid syndrome (APS) and 50 healthy controls using an enzyme-linked immunosorbent assay (ELISA) technique. We found that antibody to FVII/VIIa, a previously unrecognized and common antigen in APS, was present in 67% of patients. Frequencies of antibodies to other target antigens were: anti-beta-2 glycoprotein 1 (anti-beta 2GP1), 88%; anti-cardiolipin (anti-CL), 76%; anti-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
35
0
2

Year Published

2005
2005
2018
2018

Publication Types

Select...
7
2

Relationship

3
6

Authors

Journals

citations
Cited by 46 publications
(38 citation statements)
references
References 57 publications
1
35
0
2
Order By: Relevance
“…They are found in 70% of thrombocytopenic patients and only in 10% of APS patients with normal platelet count [40] Found in other autoimmune diseases; in SLE, similar values were obtained for thrombocytopenic (6/11) and nonthrombocytopenic patients ( 13 Antibody to factor FVII/VIIa 67% Positivity for anti-FVII/VIIa was significantly associated with positivity for antiphosphatidylethanolamine, antiphosphatidylserine and/or antiphosphatidylcholine (P < 0.05) but not anti-beta2GPI antibodies [42] Clinical correlation: significantly associated with both arterial and venous thrombosis (i) In arterial thrombosis, IgM was more prevalent for all antigens, and was significantly associated with FVII/VIIa, PE and PS (ii) In venous thrombosis, IgG was frequently prevalent, especially in association with FVII/VIIa, beta2GPI and aCL Antibodies to factor FVII/VIIa of the IgM type were correlated with LAC (P < 0.05) and were significantly more prevalent than IgM. Similar findings were found for the other antibodies mentioned above, with the exception of anti-beta2GP 14…”
Section: Lupus Anticoagulantssupporting
confidence: 76%
“…They are found in 70% of thrombocytopenic patients and only in 10% of APS patients with normal platelet count [40] Found in other autoimmune diseases; in SLE, similar values were obtained for thrombocytopenic (6/11) and nonthrombocytopenic patients ( 13 Antibody to factor FVII/VIIa 67% Positivity for anti-FVII/VIIa was significantly associated with positivity for antiphosphatidylethanolamine, antiphosphatidylserine and/or antiphosphatidylcholine (P < 0.05) but not anti-beta2GPI antibodies [42] Clinical correlation: significantly associated with both arterial and venous thrombosis (i) In arterial thrombosis, IgM was more prevalent for all antigens, and was significantly associated with FVII/VIIa, PE and PS (ii) In venous thrombosis, IgG was frequently prevalent, especially in association with FVII/VIIa, beta2GPI and aCL Antibodies to factor FVII/VIIa of the IgM type were correlated with LAC (P < 0.05) and were significantly more prevalent than IgM. Similar findings were found for the other antibodies mentioned above, with the exception of anti-beta2GP 14…”
Section: Lupus Anticoagulantssupporting
confidence: 76%
“…[119,135]. It appears that the protein cofactors responsible for positive aPE are predominately kininogens or kininogen-IC [143].…”
Section: Introductionmentioning
confidence: 99%
“…1). ELISA for APLA [6] showed positive IgM (high) and IgG (low) anticardiolipin antibodies (aCL) and positive IgM B2GP1 antibody (high) prior to rituximab. After rituximab, aCL IgM became negative but [5].…”
Section: Laboratory Investigationmentioning
confidence: 99%